000884816 001__ 884816
000884816 005__ 20220930130253.0
000884816 0247_ $$2doi$$a10.3390/pharmaceutics12100925
000884816 0247_ $$2Handle$$a2128/25804
000884816 0247_ $$2pmid$$apmid:32998351
000884816 0247_ $$2WOS$$aWOS:000587410200001
000884816 0247_ $$2altmetric$$aaltmetric:91348188
000884816 037__ $$aFZJ-2020-03273
000884816 082__ $$a610
000884816 1001_ $$0P:(DE-Juel1)131839$$aPissarek, Margit$$b0$$eCorresponding author
000884816 245__ $$aPositron Emission Tomography in the Inflamed Cerebellum: Addressing Novel Targets among G Protein-Coupled Receptors and Immune Receptors
000884816 260__ $$aBasel$$bMDPI$$c2020
000884816 3367_ $$2DRIVER$$aarticle
000884816 3367_ $$2DataCite$$aOutput Types/Journal article
000884816 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601571032_20524
000884816 3367_ $$2BibTeX$$aARTICLE
000884816 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000884816 3367_ $$00$$2EndNote$$aJournal Article
000884816 520__ $$aInflammatory processes preceding clinical manifestation of brain diseases are moving increasingly into the focus of positron emission tomographic (PET) investigations. A key role in inflammation and as a target of PET imaging efforts is attributed to microglia. Cerebellar microglia, with a predominant ameboid and activated subtype, is of special interest also regarding improved and changing knowledge on functional involvement of the cerebellum in mental activities in addition to its regulatory role in motor function. The present contribution considers small molecule ligands as potential PET tools for the visualization of several receptors recognized to be overexpressed in microglia and which can potentially serve as indicators of inflammatory processes in the cerebellum. The sphingosine 1 phosphate receptor 1 (S1P1), neuropeptide Y receptor 2 (NPY2) and purinoceptor Y12 (P2Y12) cannabinoid receptors and the chemokine receptor CX3CR1 as G-protein-coupled receptors and the ionotropic purinoceptor P2X7 provide structures with rather classical binding behavior, while the immune receptor for advanced glycation end products (RAGE) and triggering receptor expressed on the triggering receptor expressed on myeloid cells 2 (TREM2) might depend for instance on further accessory proteins. Improvement in differentiation between microglial functional subtypes in comparison to the presently used 18 kDa translocator protein ligands as well as of the knowledge on the role of polymorphisms are special challenges in such developments.
000884816 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000884816 588__ $$aDataset connected to CrossRef
000884816 773__ $$0PERI:(DE-600)2527217-2$$a10.3390/pharmaceutics12100925$$gVol. 12, no. 10, p. 925 -$$n10$$p925 -$$tPharmaceutics$$v12$$x1999-4923$$y2020
000884816 8564_ $$uhttps://juser.fz-juelich.de/record/884816/files/Invoice_MDPI_pharmaceutics-918763_1065.50EUR.pdf
000884816 8564_ $$uhttps://juser.fz-juelich.de/record/884816/files/Invoice_MDPI_pharmaceutics-918763_1065.50EUR.pdf?subformat=pdfa$$xpdfa
000884816 8564_ $$uhttps://juser.fz-juelich.de/record/884816/files/pharmaceutics-12-00925-v3.pdf$$yOpenAccess
000884816 8564_ $$uhttps://juser.fz-juelich.de/record/884816/files/pharmaceutics-12-00925-v3.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000884816 8767_ $$8918763$$92020-09-25$$d2020-10-02$$eAPC$$jZahlung erfolgt$$ppharmaceutics-918763$$zBelegnr.: 1200157792
000884816 909CO $$ooai:juser.fz-juelich.de:884816$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000884816 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131839$$aForschungszentrum Jülich$$b0$$kFZJ
000884816 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000884816 9141_ $$y2020
000884816 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000884816 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACEUTICS : 2018$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000884816 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-10
000884816 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-10
000884816 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000884816 980__ $$ajournal
000884816 980__ $$aVDB
000884816 980__ $$aUNRESTRICTED
000884816 980__ $$aI:(DE-Juel1)INM-5-20090406
000884816 980__ $$aAPC
000884816 9801_ $$aAPC
000884816 9801_ $$aFullTexts